Surna Cultivation Technologies Signs Contract for New Addition to Product Portfolio

Converted Air Sanitization Product Partnership to Customer Contract in Under Thirty Days Louisville, Colorado, April 05, 2022 (GLOBE NEWSWIRE) -- CEA Industries...

Adding Smart for Life (SMFL) $0.85 to the Watch List.

Adding another "Broken" IPO to the Watch List. We're not sure if "broken" is the appropriate description, when...

Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...

New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Courtesy Ben Mills

Glutathione: The “Mother” of all Antioxidants…

Glutathione, also known as GSH, is a molecule found naturally in your body. It is produced by the liver and nerve cells...

Revive Therapeutics (RVVTF) Regulatory Update Archive.

April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...

Stand Down. “A Super Bubble” says Jeremy Grantham, the “Day of Reckoning is Here”...

Calling a Super Bubble. | Front Row with Jeremy Grantham https://youtu.be/JlEGU2ypr1Q
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE
Revive Therapeutics $RVVTF

Amazing Sales of Paxlovid (CBS News).

"These medicines have a sweet spot. If the day you get diagnosed COVID you say 'forget it, I'll be fine,' and then...
Revive therapeutics

Our Best Risk to Reward Idea Ever?

Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...

Latest article

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!